Welcome to our dedicated page for Esperion Therapeutics SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esperion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esperion Therapeutics's regulatory disclosures and financial reporting.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of common stock of Esperion Therapeutics, Inc. in a Schedule 13G filing. They report aggregate beneficial ownership of 17,222,156.04 shares of Esperion common stock, representing 6.7% of the class. The reporting persons disclose shared voting power over 17,216,493.04 shares and shared dispositive power over 17,216,538.04 shares, with no sole voting or dispositive power. Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser, is a subsidiary of The Goldman Sachs Group, Inc., and the filing reflects securities held by specified Goldman Sachs reporting units, which disclaim beneficial ownership in certain client and managed entities.
Vanguard Capital Management reports beneficial ownership of common stock of Esperion Therapeutics Inc. Vanguard and certain affiliates hold 13,105,104 shares, representing 5.08% of Esperion’s common stock. Vanguard has sole voting power over 1,677,667 shares and sole dispositive power over 13,105,104 shares, with no shared voting or dispositive power.
The position is held across Vanguard investment companies and other managed accounts for which Vanguard and specified affiliates exercise dispositive and/or voting authority. Dividends and sale proceeds are for the benefit of these funds and clients, and no other single person has an interest in more than 5% of the class.
Wasatch Advisors reports beneficial ownership of 1,930,185 Esperion Therapeutics shares, representing 0.7% of the company’s stock class. The position carries sole voting power and sole dispositive power over all of these shares, with no shared voting or dispositive authority.
The disclosure characterizes this stake as “Ownership of 5 percent or less of a class,” indicating that Wasatch Advisors holds a relatively small fraction of Esperion’s outstanding stock.